Novo Nordisk A/S (NVO) : The total money flow in Novo Nordisk A/S (NVO) was negative ($1.07 million), showing the domination of sellers in the Tuesday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $6.36 million. Transactions on upticks were comparatively lower at $5.29 million. The uptick to downtick ratio was 0.83. The total block trades on downticks were valued at $1.03 million. The money flow during block trades was negative ($1.03 million) when the stock traded with a gain of $16 cent. Novo Nordisk A/S (NVO) was $47.21, an increase of 0.34% over the previous days close.
Also, Bank of America downgrades its rating on Novo Nordisk A/S (NYSE:NVO). Analysts at the Bank of America have a current rating of Neutral on the shares. The shares were previously rated Buy. The rating by the firm was issued on August 8, 2016.
Novo Nordisk A/S has lost 0.59% in the last five trading days and dropped 16.6% in the last 4 weeks. Novo Nordisk A/S has dropped 15.35% during the last 3-month period . Year-to-Date the stock performance stands at -16.63%.
Novo Nordisk A/S (NYSE:NVO): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $46.92 and $46.90 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $47.32. The buying momentum continued till the end and the stock did not give up its gains. It closed at $47.13, notching a gain of 0.17% for the day. The total traded volume was 1,219,326 . The stock had closed at $47.05 on the previous day.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.